このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

コントロールされていない喘息の成人参加者を対象とした、FF/UMEC/VI と非エリプタ通常治療 ICS-LABA の実用的なオープンラベルランダム化臨床試験 (PERFORM)

2026年9月11日 更新者：GlaxoSmithKline

フェーズ 4、52 週間 (24 週間での一次解析)、無作為化、層別化、非盲検、実薬対照、並行群間有効性試験、FF/UMEC/VI とエリプタ以外の通常治療 (ICS/ LABA) 喘息がコントロールされていない成人参加者における

The goal of this study is to assess and compare the effectiveness of fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (FF/UMEC/VI) with inhaled corticosteroids/long-acting beta-2 agonists (ICS/LABA) in adult participants with uncontrolled asthma

調査の概要

状態

積極的、募集していない

条件

介入・治療

研究の種類

介入

入学 (実際)

1358

段階

  • フェーズ 4

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

  • アメリカ
    • Alabama
      • Centreville、Alabama、アメリカ、35042
        • GSK Investigational Site
    • Arkansas
      • Little Rock、Arkansas、アメリカ、72205
        • GSK Investigational Site
    • California
      • Newport Beach、California、アメリカ、92663
        • GSK Investigational Site
    • Delaware
      • Newark、Delaware、アメリカ、08901
        • GSK Investigational Site
    • Florida
      • Clearwater、Florida、アメリカ、33765-2150
        • GSK Investigational Site
      • Miami、Florida、アメリカ、33126
        • GSK Investigational Site
      • Miami、Florida、アメリカ、33135
        • GSK Investigational Site
      • Miami、Florida、アメリカ、33173-3484
        • GSK Investigational Site
      • North Miami Beach、Florida、アメリカ、33169
        • GSK Investigational Site
      • Orlando、Florida、アメリカ、32819
        • GSK Investigational Site
      • Palm Springs、Florida、アメリカ、33406
        • GSK Investigational Site
      • Port Charlotte、Florida、アメリカ、33952
        • GSK Investigational Site
      • Tallahassee、Florida、アメリカ、32308
        • GSK Investigational Site
    • Illinois
      • Normal、Illinois、アメリカ、61761
        • GSK Investigational Site
    • Louisiana
      • New Orleans、Louisiana、アメリカ、20852
        • GSK Investigational Site
    • Maine
      • Bangor、Maine、アメリカ、04401
        • GSK Investigational Site
    • Michigan
      • Detroit、Michigan、アメリカ、48202
        • GSK Investigational Site
      • Warren、Michigan、アメリカ、48088
        • GSK Investigational Site
    • Montana
      • Missoula、Montana、アメリカ、59804
        • GSK Investigational Site
    • Nebraska
      • Papillion、Nebraska、アメリカ、68046
        • GSK Investigational Site
    • New Jersey
      • Brick、New Jersey、アメリカ、08724
        • GSK Investigational Site
      • Linwood、New Jersey、アメリカ、08221
        • GSK Investigational Site
    • New York
      • New Windsor、New York、アメリカ、12553-7754
        • GSK Investigational Site
    • North Carolina
      • Asheville、North Carolina、アメリカ、28801
        • GSK Investigational Site
      • Charlotte、North Carolina、アメリカ、28273
        • GSK Investigational Site
      • Greenville、North Carolina、アメリカ、27834
        • GSK Investigational Site
      • Winston-Salem、North Carolina、アメリカ、27104
        • GSK Investigational Site
    • Ohio
      • Cincinnati、Ohio、アメリカ、45231
        • GSK Investigational Site
    • Pennsylvania
      • DuBois、Pennsylvania、アメリカ、15801-2277
        • GSK Investigational Site
      • Philadelphia、Pennsylvania、アメリカ、19140
        • GSK Investigational Site
      • Pittsburgh、Pennsylvania、アメリカ、15241
        • GSK Investigational Site
    • South Carolina
      • Rock Hill、South Carolina、アメリカ、29732
        • GSK Investigational Site
      • Spartanburg、South Carolina、アメリカ、29303-4225
        • GSK Investigational Site
    • Texas
      • Beaumont、Texas、アメリカ、77701
        • GSK Investigational Site
      • Dallas、Texas、アメリカ、75225
        • GSK Investigational Site
    • Washington
      • Bellingham、Washington、アメリカ、98225
        • GSK Investigational Site
  • アルゼンチン
      • Buenos Aires、アルゼンチン、C1425BEN
        • GSK Investigational Site
      • Buenos Aires、アルゼンチン、C1128AAF
        • GSK Investigational Site
      • Buenos Aires、アルゼンチン、C1192AAW
        • GSK Investigational Site
      • Buenos Aires、アルゼンチン、FVH1425
        • GSK Investigational Site
      • Ciudad Autonoma de Buenos Aire、アルゼンチン、1012
        • GSK Investigational Site
      • Concepción del Uruguay、アルゼンチン、3260
        • GSK Investigational Site
      • Córdoba、アルゼンチン、X5003DCE
        • GSK Investigational Site
      • Formosa、アルゼンチン、3600
        • GSK Investigational Site
      • Lujan de Cuyo、アルゼンチン、5509
        • GSK Investigational Site
      • Luján、アルゼンチン、6700
        • GSK Investigational Site
      • Mar del Plata、アルゼンチン、7600
        • GSK Investigational Site
      • Mendoza、アルゼンチン、5500
        • GSK Investigational Site
      • Mendoza、アルゼンチン、5577
        • GSK Investigational Site
      • Mendoza、アルゼンチン、M5500
        • GSK Investigational Site
      • Quilmes、アルゼンチン、1878
        • GSK Investigational Site
      • Rosario、アルゼンチン、2000
        • GSK Investigational Site
      • Rosario、アルゼンチン、S2000DBS
        • GSK Investigational Site
      • Rosario、アルゼンチン、S2000 DEJ
        • GSK Investigational Site
      • San Juan Bautista、アルゼンチン、1888
        • GSK Investigational Site
      • San Miguel de Tucumán、アルゼンチン、T4000AXL
        • GSK Investigational Site
      • Santa Fe、アルゼンチン、3000
        • GSK Investigational Site
  • オーストラリア
    • Australian Capital Territory
      • Bruce、Australian Capital Territory、オーストラリア、2617
        • GSK Investigational Site
    • New South Wales
      • Blacktown、New South Wales、オーストラリア、2148
        • GSK Investigational Site
      • Coffs Harbour、New South Wales、オーストラリア、2450
        • GSK Investigational Site
      • Kanwal、New South Wales、オーストラリア、2259
        • GSK Investigational Site
      • Sydney、New South Wales、オーストラリア、2035
        • GSK Investigational Site
    • Queensland
      • Brisbane、Queensland、オーストラリア、4006
        • GSK Investigational Site
    • Western Australia
      • Osborne Park、Western Australia、オーストラリア、6017
        • GSK Investigational Site
      • Spearwood、Western Australia、オーストラリア、6163
        • GSK Investigational Site
  • カナダ
    • Ontario
      • Windsor、Ontario、カナダ、N8X 1T3
        • GSK Investigational Site
    • Quebec
      • Trois-Rivières、Quebec、カナダ、G9A 4P3
        • GSK Investigational Site
  • 中国
      • Nanshan District、中国、518067
        • GSK Investigational Site
      • Zhuhai、中国、519099
        • GSK Investigational Site
    • Foshan City
      • Chancheng District、Foshan City、中国、528031
        • GSK Investigational Site
    • Guangzhou
      • Liwan District、Guangzhou、中国、510160
        • GSK Investigational Site
    • Jiangmen City
      • North Street、Jiangmen City、中国、52900
        • GSK Investigational Site
  • 台湾
      • Kaohsiung City、台湾、807
        • GSK Investigational Site
      • Taichung、台湾、40447
        • GSK Investigational Site
      • Taichung、台湾、407219
        • GSK Investigational Site
      • Taipei、台湾、10002
        • GSK Investigational Site
  • 日本
      • Fukuoka、日本、807-8555
        • GSK Investigational Site
      • Fukuoka、日本、820-8505
        • GSK Investigational Site
      • Fukuoka、日本、816-0813
        • GSK Investigational Site
      • Fukuoka、日本、832-0059
        • GSK Investigational Site
      • Fukuoka、日本、802-0083
        • GSK Investigational Site
      • Gifu、日本、509-6134
        • GSK Investigational Site
      • Hiroshima、日本、730-0853
        • GSK Investigational Site
      • Hiroshima、日本、730-0013
        • GSK Investigational Site
      • Hiroshima、日本、733-0002
        • GSK Investigational Site
      • Hyōgo、日本、651-0053
        • GSK Investigational Site
      • Kagawa、日本、761-8073
        • GSK Investigational Site
      • Kagoshima、日本、890-0053
        • GSK Investigational Site
      • Kanagawa、日本、252-0143
        • GSK Investigational Site
      • Kumamoto、日本、860-8556
        • GSK Investigational Site
      • Kumamoto、日本、862-0965
        • GSK Investigational Site
      • Matsuyama、日本、790-0925
        • GSK Investigational Site
      • Miyagi、日本、980-0871
        • GSK Investigational Site
      • Miyazaki、日本、880-2112
        • GSK Investigational Site
      • Miyazaki、日本、889-4304
        • GSK Investigational Site
      • Nagaoka-Shi、日本、940-0087
        • GSK Investigational Site
      • Niigata、日本、950-0088
        • GSK Investigational Site
      • Okawa-shi、日本、831-0016
        • GSK Investigational Site
      • Shinjuku-kuTokyo、日本、160-0021
        • GSK Investigational Site
      • Tokyo、日本、160-0017
        • GSK Investigational Site
      • Tokyo、日本、142-8666
        • GSK Investigational Site
      • Tokyo、日本、157-0066
        • GSK Investigational Site
      • Tokyo、日本、173-8606
        • GSK Investigational Site
      • Tokyo、日本、145-0063
        • GSK Investigational Site
      • Tokyo、日本、105-0001
        • GSK Investigational Site
      • Yokohama、日本、223-0053
        • GSK Investigational Site
      • Ōita、日本
        • GSK Investigational Site
  • 韓国
      • Busan、韓国、602 702
        • GSK Investigational Site
      • Daegu、韓国、41404
        • GSK Investigational Site
      • Seongnam-si Gyeonggi-do、韓国、13620
        • GSK Investigational Site
      • Seoul、韓国、03080
        • GSK Investigational Site
      • Seoul、韓国、02841
        • GSK Investigational Site
      • Seoul、韓国、133-792
        • GSK Investigational Site
      • Seoul、韓国、158-710
        • GSK Investigational Site
      • Seoul、韓国、07061
        • GSK Investigational Site
      • Seoul、韓国、5030
        • GSK Investigational Site
      • Suwon Kyunggi-do、韓国、16499
        • GSK Investigational Site

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年～75年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

Participants are eligible to be included in the study only if all of the following criteria apply:

  1. Has a diagnosis of asthma as defined by Global Initiative for Asthma (GINA) 2023 guidelines for at least 3 months prior to randomization.

  2. Participants who are either:

    • Currently untreated
    • Treated with daily maintenance ICS or ICS/LABA

  3. ACQ-6 score ≥1.5 at randomization.

  4. Participants able to perform technically acceptable and repeatable FEV1 maneuvers (i.e., a minimum of 2 acceptable and 1 repeatable effort) at visit 2 (V2)

  5. Participants must be able to complete the study questionnaires.

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  1. Recent history of life-threatening asthma
  2. History of >1 severe exacerbation of asthma within 12 months prior to randomization.
  3. Women of childbearing potential that are not following at least one highly effective method of contraception. This includes women who are pregnant or lactating or are planning on becoming pregnant during the study.
  4. A WOCBP must have a negative pregnancy test ≤7 days prior to randomization.
  5. Exposure to inhaler triple therapy [ICS + Long-acting muscarinic antagonist (LAMA) + LABA as Single inhaler triple therapy (SITT) or Multiple inhaler triple therapy(MITT)] and/or any LAMA-containing therapy within 12 months prior to randomization.
  6. Ongoing need for biologic therapy or recent use of a biologic therapy
  7. Participants with the diagnosis of chronic obstructive pulmonary disease, as per Global Initiative for Chronic Obstructive Lung Disease (GOLD 2024) guidelines.
  8. Participants whose current medications include RELVAR ELLIPTA and ARNUITY ELLIPTA are not eligible to enter the study.
  9. Participants who are medically unable to withhold their albuterol/salbutamol for 6 hours prior to spirometry testing
  10. Changes in asthma medication (e.g., maintenance ICS/LABA) within 3 months prior to randomization.
  11. Participants with a history of hypersensitivity to any of the study medications

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか？

デザインの詳細

  • 主な目的：処理
  • 割り当て：ランダム化
  • 介入モデル：並列代入
  • マスキング：なし（オープンラベル）

武器と介入

参加者グループ / アーム
介入・治療
実験的：Fluticasone Furoate [FF]/ Umeclidinium [UMEC]/ Vilanterol [VI]

Participants with uncontrolled asthma were randomized to receive a once-daily (QD) fixed-dose combination of 100 microgram (mcg) fluticasone furoate (FF), 62.5 mcg umeclidinium (UMEC), and 25 mcg vilanterol (VI) via the Ellipta dry powder inhaler (DPI) for up to 24 weeks. At the discretion of the investigator, a subset of participants received the high-dose ICS-containing therapy, FF/UMEC/VI 200/62.5/25 instead. At any time during the study (post-randomization), participants were escalated to receive FF/UMEC/VI 200/62.5/25 mcg if their asthma control worsened significantly, defined as an increase in Asthma Control Questionnaire (ACQ-7) total score of >0.5 from baseline and the physician determines increased Inhaled Corticosteroid [ICS] is ethically necessary.
薬：Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate

Participants will receive FF/UMEC/VI
アクティブコンパレータ：Inhaled Corticosteroid [ICS]/Long-acting beta-2 agonist [LABA]

Participants with uncontrolled asthma were randomized to receive Inhaled Corticosteroid [ICS]/Long-acting beta-2 agonist [LABA] based on usual care as per the country specific regulatory labels up to 24 weeks. At the discretion of the investigator, a subset of participants received high-dose ICS/LABA. At any time during the study (post-randomization), participants were escalated to receive high dose ICS/LABA if their asthma control worsened significantly, defined as an increase in ACQ-7 total score of >0.5 from baseline and the physician determines increased ICS is ethically necessary.
薬：Inhaled corticosteroids/long-acting beta-2 agonists

Participants will receive ICS/LABA

この研究は何を測定していますか？

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change From Baseline (CFB) in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24
時間枠：Baseline (Day 1) and at Week 24

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value
Baseline (Day 1) and at Week 24

二次結果の測定

結果測定
メジャーの説明
時間枠
Percentage of Participants Achieving Greater Than Equal to (>=) 0.5 Point Improvement (Decrease) From Baseline for the Asthma Control Questionnaire-7 (ACQ-7) at Week 24
時間枠：Baseline (Day 1) and at Week 24

The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath, and wheeze) with response options ranging from 0 (no impairment/limitation) to 6 (total impairment/ limitation).ACQ-7 total score is the mean of the responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to (<=)0.75 indicates well-controlled asthma, a score of between 0.75 and 1.5 indicates partially controlled asthma, and a score >=1.5 indicates poorly controlled asthma. Greater than or equal to 0.5 point decrease from baseline suggests a clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Percentage values are rounded off.
Baseline (Day 1) and at Week 24
Percentage of Participants Achieving the Composite Endpoint (Optimized) at Week 52
時間枠：Baseline (Day 1) and at Week 52

The 4-point composite endpoint is defined as meeting the following criteria: Change from baseline in trough FEV1 >= 100 milliliter (mL) at Week 52, Controlled asthma based on ACQ-5 total score <= 1.5 at Week 52, No severe asthma exacerbations over 52 weeks and oral corticosteroids (OCS)-free over 52 weeks
Baseline (Day 1) and at Week 52
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 52
時間枠：Baseline (Day 1) and at Week 52

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1).
Baseline (Day 1) and at Week 52
Percentage of Participants With Change From Baseline in Trough FEV1 >= 100 mL at Week 24
時間枠：Baseline (Day 1) and at Week 24

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value. Percentage values are rounded-off.
Baseline (Day 1) and at Week 24
Percentage of Participants With Change From Baseline in Trough FEV1 >= 100 mL at Week 52
時間枠：Baseline (Day 1) and at Week 52

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1).
Baseline (Day 1) and at Week 52
Percentage of Participants With Change From Baseline in Trough FEV1 >= 0 mL at Week 24
時間枠：Baseline (Day 1) and at Week 24

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value. Percentage values are rounded-off.
Baseline (Day 1) and at Week 24
Percentage of Participants With Change From Baseline in Trough FEV1 >= 0 mL at Week 52
時間枠：Baseline (Day 1) and at Week 52

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1).
Baseline (Day 1) and at Week 52
Percentage of Participants Achieving >= 0.5 Point Improvement (Decrease) From Baseline for the ACQ-7 Score at Week 52
時間枠：Baseline (Day 1) and at Week 52

The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze) with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is the mean of the responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to (<=) 0.75 indicates well-controlled asthma, a score of between 0.75 and 1.5 indicates partially controlled asthma, and a score >= 1.5 indicates poorly controlled asthma. Greater than or equal to 0.5 point decrease from baseline suggests a clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Baseline (Day 1) and at Week 52
Percentage of Participants Achieving >=0.5 Point Improvement (Decrease) From Baseline for the ACQ-6 Score at Week 24
時間枠：Baseline (Day 1) and at Week 24

The ACQ-6 is a shortened version of the ACQ-7 derived by removing one element (lung function element) from the original version. ACQ-6 consists of 6 questions scored from zero (no impairment/limitation) to six (total impairment/ limitation). Higher scores indicate greater impairment. Mean scores of <=0.75 indicate well-controlled asthma, scores between 0.75 and 1.5 indicate partially controlled asthma, and scores >=1.5 indicate poorly controlled asthma. A decrease in ACQ-6 score from Baseline indicates an improvement in asthma control, and individual changes of at least 0.5 are considered clinically meaningful. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Percentage values are rounded off.
Baseline (Day 1) and at Week 24
Percentage of Participants Achieving >=0.5 Point Improvement (Decrease) From Baseline for the ACQ-6 Score at Week 52
時間枠：Baseline (Day 1) and at Week 52

The ACQ-6 is a shortened version of the ACQ-7 derived by removing one element (lung function element) from the original version. ACQ-6 consists of 6 questions scored from zero (no impairment/limitation) to six (total impairment/ limitation). Higher scores indicate greater impairment. Mean scores of <=0.75 indicate well-controlled asthma, scores between 0.75 and 1.5 indicate partially controlled asthma, and scores >=1.5 indicate poorly controlled asthma. A decrease in ACQ-6 score from Baseline indicates an improvement in asthma control, and individual changes of at least 0.5 are considered clinically meaningful. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Baseline (Day 1) and at Week 52
Percentage of Participants Achieving >=0.5 Point Improvement (Decrease) From Baseline for the ACQ-5 Score at Week 24
時間枠：Baseline (Day 1) and at Week 24

The ACQ-5 is a five-item questionnaire designed to be self-completed by the participants to assess the most common asthma symptoms. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze). The overall ACQ-5 response option is the mean score of all 5 questions representing 0=no impairment/limitation and 6=total impairment/ limitation. Higher scores indicated more limitations and lower scores indicated better asthma control. Higher score indicates worse symptoms. Greater than or equal to 0.5 point decrease from baseline suggests a clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Percentage values are rounded-off.
Baseline (Day 1) and at Week 24
Percentage of Participants Achieving >=0.5 Point Improvement (Decrease) From Baseline for the ACQ-5 at Week 52
時間枠：Baseline (Day 1) and at Week 52

The ACQ-5 is a five-item questionnaire designed to be self-completed by the participants to assess the most common asthma symptoms. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze). The overall ACQ-5 response option is the mean score of all 5 questions representing 0=no impairment/limitation and 6=total impairment/ limitation. Higher scores indicated more limitations and lower scores with better asthma control. Higher score indicates worse symptoms. Greater than or equal to 0.5 point decrease from Baseline suggests a clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Baseline (Day 1) and at Week 52
Change From Baseline (CFB) in the ACQ-7 Total Score at Week 24
時間枠：Baseline (Day 1) and at Week 24

The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath, and wheeze) with response options ranging from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is the mean of the responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to 0.75 indicates well-controlled asthma, a score of between 0.75 and 1.5 indicates partially controlled asthma, and a score >=1.5 indicates poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value
Baseline (Day 1) and at Week 24
Change From Baseline (CFB) in the ACQ-7 Total Score at Week 52
時間枠：Baseline (Day 1) and at Week 52

The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath, and wheeze) with response options ranging from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is the mean of the responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to 0.75 indicates well-controlled asthma, a score of between 0.75 and 1.5 indicates partially controlled asthma, and a score >=1.5 indicates poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Baseline (Day 1) and at Week 52
Change From Baseline (CFB) in the ACQ-6 Total Score at Week 24
時間枠：Baseline (Day 1) and at Week 24

The ACQ-6 is a shortened version of the ACQ-7 derived by removing one element (lung function element) from the original version. ACQ-6 consists of 6 questions scored from zero (no impairment/limitation) to six (total impairment/ limitation). Higher scores indicate greater impairment. Mean scores of <=0.75 indicate well-controlled asthma, scores between 0.75 and 1.5 indicate partially controlled asthma, and scores >=1.5 indicate poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.
Baseline (Day 1) and at Week 24
Change From Baseline (CFB) in the ACQ-6 Total Score at Week 52
時間枠：Baseline (Day 1) and at Week 52

The ACQ-6 is a shortened version of the ACQ-7 derived by removing one element (lung function element) from the original version. ACQ-6 consists of 6 questions scored from zero (no impairment/limitation) to six (total impairment/ limitation). Higher scores indicate greater impairment. Mean scores of <=0.75 indicate well-controlled asthma, scores between 0.75 and 1.5 indicate partially controlled asthma, and scores >=1.5 indicate poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Baseline (Day 1) and at Week 52
Change From Baseline (CFB) in the ACQ-5 Total Score at Week 24
時間枠：Baseline (Day 1) and at Week 24

The ACQ-5 is a five-item questionnaire designed to be self-completed by the participants to assess the most common asthma symptoms. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze). The overall ACQ-5 response option is the mean score of all 5 questions representing 0=no impairment/limitation and 6=total impairment/limitation. Higher scores indicated more limitations and lower scores indicated better asthma control. Higher score indicates worse symptoms. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.
Baseline (Day 1) and at Week 24
Change From Baseline (CFB) in the ACQ-5 Total Score at Week 52
時間枠：Baseline (Day 1) and at Week 52

The ACQ-5 is a five-item questionnaire designed to be self-completed by the participants to assess the most common asthma symptoms. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze). The overall ACQ-5 response option is the mean score of all 5 questions representing 0=no impairment/limitation and 6=total impairment/limitation. Higher scores indicated more limitations and lower scores indicated better asthma control. Higher score indicates worse symptoms. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Baseline (Day 1) and at Week 52
Change From Baseline (CFB) in the Asthma Control Test (ACT) Score at Week 24
時間枠：Baseline (Day 1) and at Week 24

The ACT is a validated self-completed questionnaire utilizing 5 questions to assess asthma control on a 5-point categorical scale ranging from 1 (not controlled at all) to 5 (completely controlled) with higher scores indicating better control. Total ACT score is calculated as the sum of the scores from the 5 questions and can range from 5 to 25, with higher scores indicating better control. An ACT total score of 5 to 15 suggests that the participant's asthma is poorly controlled, a score of 16 to 19 suggests that the participant's asthma is somewhat controlled, and a score of 20 to 25 suggests that the participant's asthma is well controlled. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. CFB was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.
Baseline (Day 1) and at Week 24
Change From Baseline (CFB) in the Asthma Control Test (ACT) Score at Week 52
時間枠：Baseline (Day 1) and at Week 52

The ACT is a validated self-completed questionnaire utilizing 5 questions to assess asthma control on a 5-point categorical scale ranging from 1 (not controlled at all) to 5 (completely controlled) with higher scores indicating better control. Total ACT score is calculated as the sum of the scores from the 5 questions and can range from 5 to 25, with higher scores indicating better control. An ACT total score of 5 to 15 suggests that the participant's asthma is poorly controlled, a score of 16-to 19 suggests that the participant's asthma is somewhat controlled, and a score of 20 to 25 suggests that the participant's asthma is well controlled. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Baseline (Day 1) and at Week 52
Percentage of Participants Achieving the Composite Endpoint (Optimized) Subset on Participants Receiving ICS/LABA Prior to Randomization at Week 52
時間枠：Baseline (Day 1) and at Week 52

The 4-point composite endpoint is defined as meeting the following criteria: 1. Change from baseline in trough FEV1 ≥ 100 mL at Week 52; 2. Controlled asthma based on ACQ-5 total score <= 1.5 at Week 52; 3. No severe asthma exacerbations over 52 weeks; 4. OCS-free over 52 weeks. Subset on participants receiving ICS/LABA prior to randomization.
Baseline (Day 1) and at Week 52
Percentage of Participants Achieving the Composite Endpoint (Optimized) Subset on Participants Receiving no Treatment Prior to Randomization at Week 52
時間枠：Baseline (Day 1) and at Week 52

The 4-point composite endpoint is defined as meeting the following criteria: 1. Change from baseline in trough FEV1 ≥ 100 mL at Week 52; 2. Controlled asthma based on ACQ-5 total score <= 1.5 at Week 52; 3. No severe asthma exacerbations over 52 weeks; 4. OCS-free over 52 weeks. Subset on participants receiving no treatment prior to randomization (no ICS-containing therapy within the 3 months prior to randomization).
Baseline (Day 1) and at Week 52
Change From Baseline (CFB) in the Asthma Quality of Life Questionnaire (AQLQ-12) Total Score at Week 24
時間枠：Baseline (Day 1) and at Week 24

AQLQ-12 is a disease-specific, self-administered quality of life questionnaire used to evaluate impact of asthma treatments on quality of life of asthma sufferers. AQLQ-12 has 32 items in 4 domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), environmental stimuli (4 items). For 32 items on questionnaire, response format consists of a 7-point scale, where 1 indicates "total impairment" and 7 indicates "no impairment." AQLQ-12 total score is defined as average of scores from all 32 questions; thus, total score ranges from 1="total impairment" to 7=indicates "no impairment". Higher score is better asthma-related health-related quality of life. Baseline is last non-missing value prior to or on prescription date of study intervention. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.
Baseline (Day 1) and at Week 24
Change From Baseline (CFB) in the Asthma Quality of Life Questionnaire (AQLQ-12) Total Score at Week 52
時間枠：Baseline (Day 1) and at Week 52

AQLQ-12 is a disease-specific, self-administered quality of life questionnaire to evaluate impact of asthma treatments on quality of life of asthma sufferers. AQLQ-12 has 32 items in 4 domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), environmental stimuli (4 items). For 32 items on questionnaire, response format consists of a 7-point scale, where a value of 1 indicates "total impairment" and a value of 7 indicates "no impairment." AQLQ-12 total score is defined as average of scores from all 32 questions; thus, total score ranges from 1="total impairment" to 7="no impairment". Higher score is better asthma-related health-related quality of life. Baseline is last non-missing value prior to or on prescription date of study intervention.
Baseline (Day 1) and at Week 52
Change From Baseline (CFB) in the Asthma Quality of Life Questionnaire (AQLQ-12) Domain Score at Week 24
時間枠：Baseline (Day 1) and at Week 24

AQLQ-12 is a disease-specific, self-administered quality of life questionnaire used to evaluate impact of asthma treatments on quality of life of asthma sufferers. AQLQ-12 has 32 items in 4 domains: symptoms (12 items), environmental stimuli (4 items), activity limitation (11 items), emotional function (5 items). For 32 items on questionnaire, response format consists of a 7-point scale, where 1 indicates "total impairment" and 7 indicates "no impairment." AQLQ-12 each domain score total score is defined as average of scores from all the 32 questions from the respective domain; thus, each domain total score ranges from 1="total impairment" to 7=indicates "no impairment". Higher score is better asthma-related health-related quality of life. Each domain score is the mean of item scores within that domain. Baseline is last non-missing value prior to or on prescription date of study intervention. CFB was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.
Baseline (Day 1) and at Week 24
Change From Baseline (CFB) in the Asthma Quality of Life Questionnaire (AQLQ-12) Domain Score at Week 52
時間枠：Baseline (Day 1) and at Week 52

AQLQ-12 is a disease-specific, self-administered quality of life questionnaire used to evaluate impact of asthma treatments on quality of life of asthma sufferers. AQLQ-12 has 32 items in 4 domains: symptoms (12 items), environmental stimuli (4 items), activity limitation (11 items), emotional function (5 items). For 32 items on questionnaire, response format consists of a 7-point scale, where 1 indicates "total impairment" and 7 indicates "no impairment." AQLQ-12 each domain score total score is defined as average of scores from all the 32 questions from the respective domain; thus, each domain total score ranges from 1="total impairment" to 7=indicates "no impairment". Higher score is better asthma-related health-related quality of life. Each domain score is the mean of item scores within that domain. Baseline is last non-missing value prior to or on prescription date of study intervention.
Baseline (Day 1) and at Week 52
Change From Baseline (CFB) in the Four Domains of the Asthma-specific Adaptation of the Work Productivity and Activity Impairment (WPAI) Questionnaire at Week 24
時間枠：Baseline (Day 1) and at Week 24

WPAI questionnaire measures impact due to poor health due to asthma on work and regular activities, yielding 4 percentage-based impairment scores, each ranges from 0 to 100%. Higher values=greater impairment and less productivity. Calculation of these 4 scores are as follows: 1. Work time missed due to health (Absenteeism)=hours missed due to health divided by (hours missed due to health+hours missed for other reasons+hours actually worked) *100. 2. Impairment while working due to health (Presenteeism) =Question (Q)5 score (from 0 to 10) divided by 10*100. 3. Overall work impairment due to health =Absenteeism+(1-Absenteeism fraction)*Presenteeism. 4. Activity impairment due to health =Q6 score (from 0 to 10) divided by 10*100. Baseline is last non-missing value prior to or on prescription date of study intervention. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.
Baseline (Day 1) and at Week 24
Change From Baseline in the Four Domains of the Asthma-specific Adaptation of the Work Productivity and Activity Impairment Questionnaire at Week 52
時間枠：Baseline (Day 1) and at Week 52

WPAI questionnaire measures impact due to poor health due to asthma on work and regular activities, yielding 4 percentage-based impairment scores, each ranges from 0 to 100%. Higher value=greater impairment and less productivity. Calculation of these 4 scores are as follows: 1. Work time missed due to health (Absenteeism) =hours missed due to health divided by (hours missed due to health+hours missed for other reasons+hours actually worked) *100. 2. Impairment while working due to health (Presenteeism) =Question (Q)5 score (from 0 to 10) divided by 10*100. 3. Overall work impairment due to health =Absenteeism+(1-Absenteeism fraction)*Presenteeism. 4. Activity impairment due to health =Q6 score (from 0 to 10) divided by 10*100. Baseline is last non-missing value prior to or on prescription date of study intervention.
Baseline (Day 1) and at Week 52
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24 Among Participants on ICS/LABA Prior to Randomization
時間枠：Baseline (Day 1) and Week 24

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1). Per Protocol the study's subgroup analysis design, the analysis for this endpoint at Week 24 will be performed based on results from the composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of End of Study (EOS) date.
Baseline (Day 1) and Week 24
Percentage of Participants Achieving >=0.5 Points Improvement (Decrease) From Baseline for ACQ-7 at Week 24 Among Participants on ICS/LABA Prior to Randomization
時間枠：Baseline (Day 1) and at Week 24

The ACQ-7 measures 7 attributes of asthma control & includes 5 symptom questions (nocturnal awakening,symptoms on waking in morning,activity limitation,shortness of breath & wheeze). Responses ranges from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is mean of the responses of 7 items, ranges from 0 to 6. Higher score = poor control. A score of <= 0.75 is well-controlled asthma; a score between 0.75 and 1.5 is partially controlled asthma & a score >= 1.5 is poorly controlled asthma. >= 0.5 point decrease from baseline is clinically important change in asthma control. Baseline is last non-missing value prior to or on the prescription date of study intervention. Per Protocol study's subgroup analysis design, analysis for this endpoint at Week 24 will be performed based on results from composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of EOS date.
Baseline (Day 1) and at Week 24
Percentage of Participants Achieving >=0.5 Points Improvement (Decrease) From Baseline for ACQ-7 at Week 52 Among Participants on ICS/LABA Prior to Randomization
時間枠：Baseline (Day 1) and at Week 52

The ACQ-7 measures 7 attributes of asthma control & includes 5 symptom questions (nocturnal awakening,symptoms on waking in the morning,activity limitation,shortness of breath & wheeze). Responses ranges from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is mean of the responses of the 7 items, ranges from 0 to 6. Higher score = poor control. A score of <= 0.75 is well-controlled asthma; a score between 0.75 and 1.5 is partially controlled asthma & a score >= 1.5 is poorly controlled asthma. >= 0.5 point decrease from baseline is clinically important change in asthma control. Baseline is last non-missing value prior to or on the prescription date of study intervention.
Baseline (Day 1) and at Week 52
Change From Baseline in the ACQ-7 Total Score at Week 24 Among Participants on ICS/LABA Prior to Randomization
時間枠：Baseline (Day 1) and at Week 24

The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions with response options ranging from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is mean of responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to 0.75 indicates well-controlled asthma, a score between 0.75 and 1.5 indicates partially controlled asthma, and a score >=1.5 indicates poorly controlled asthma. Baseline is defined as last non-missing value prior to or on prescription date of study intervention. Per Protocol the study's subgroup analysis design, the analysis for this endpoint at Week 24 will be performed based on results from the composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of End of Study date.
Baseline (Day 1) and at Week 24
Change From Baseline (CFB) in the ACQ-7 Total Score at Week 52 Among Participants on ICS/LABA Prior to Randomization
時間枠：Baseline (Day 1) and at Week 52

The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath, and wheeze) with response options ranging from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is the mean of the responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to 0.75 indicates well-controlled asthma, a score between 0.75 and 1.5 indicates partially controlled asthma, and a score >=1.5 indicates poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Baseline (Day 1) and at Week 52
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24 for Participants With no Treatment Prior to Randomization
時間枠：Baseline (Day 1) and Week 24

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1). Per Protocol the study's subgroup analysis design, the analysis for this endpoint at Week 24 will be performed based on results from the composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of End of Study date.
Baseline (Day 1) and Week 24
Percentage of Participants Achieving >=0.5 Points Improvement (Decrease) From Baseline for ACQ-7 at Week 24 for Participants With no Treatment Prior to Randomization.
時間枠：Baseline (Day 1) and at Week 24

The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze) with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation). A score of <=0.75 indicates well-controlled asthma and a score >=1.5 indicates poorly controlled asthma. >= 0.5 point decrease from baseline is clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Per Protocol the study's subgroup analysis design, the analysis for this endpoint at Week 24 will be performed based on results from the composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of End of Study date.
Baseline (Day 1) and at Week 24
Percentage of Participants Achieving >=0.5 Points Improvement (Decrease) From Baseline for ACQ-7 at Week 52 for Participants With no Treatment Prior to Randomization
時間枠：Baseline (Day 1) and at Week 52

The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze). Response ranges from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is mean of the responses of 7 items, ranges from 0 to 6. Higher score = poor control. A score of <=0.75 indicates is well-controlled asthma; and a score >=1.5 indicates poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Baseline (Day 1) and at Week 52
Change From Baseline (CFB) in the ACQ-7 Total Score at Week 24 for Participants With no Treatment Prior to Randomization
時間枠：Baseline (Day 1) and at Week 24

The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze) with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation). A score of less than equal to 0.75 indicates well-controlled asthma, a score between 0.75 and 1.5 indicates partially controlled asthma, and a score >=1.5 indicates poorly controlled asthma. A change of 0.5 in score suggests a clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Per Protocol the study's subgroup analysis design, the analysis for this endpoint at Week 24 will be performed based on results from the composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of End of Study date.
Baseline (Day 1) and at Week 24
Change From Baseline (CFB) in the ACQ-7 Total Score at Week 52 for Participants With no Treatment Prior to Randomization
時間枠：Baseline (Day 1) and at Week 52

The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze) with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation). A score of less than equal to 0.75 indicates well-controlled asthma, a score of between 0.75 and 1.5 indicates partially controlled asthma, and a score >=1.5 indicates poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.
Baseline (Day 1) and at Week 52

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

GlaxoSmithKline

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年4月16日

一次修了 (実際)

2025年7月28日

研究の完了 (推定)

2027年6月14日

試験登録日

最初に提出

2024年4月15日

QC基準を満たした最初の提出物

2024年4月15日

最初の投稿 (実際)

2024年4月18日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月6日

QC基準を満たした最後の更新が送信されました

2026年9月11日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

キーワード

追加の関連 MeSH 用語

その他の研究ID番号

  • 219912

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

IPD 共有時間枠

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

IPD 共有アクセス基準

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する